Brief: Prestige Biopharma & Dr. Reddy's Announce Partnership To Commercialize Trastuzumab Biosimilar In Some Countries In Latin America & Southeast Asia
14/12/2021 17:26
Dec 14 (Reuters) - Prestige Biopharma Ltd 950210.KS :
* PRESTIGE BIOPHARMA AND DR. REDDY'S ANNOUNCE PARTNERSHIP TO
COMMERCIALIZE TRASTUZUMAB BIOSIMILAR IN SELECT COUNTRIES IN
LATIN AMERICA AND SOUTHEAST ASIA
* PRESTIGE BIOPHARMA - WILL BE RESPONSIBLE FOR SUSTAINABLE
COMMERCIAL SUPPLY OF HD201 FROM MANUFACTURING FACILITIES IN
OSONG, SOUTH KOREA UNDER DEAL
* PRESTIGE BIOPHARMA LTD - DR. REDDY'S WILL BE RESPONSIBLE
FOR
LOCAL REGISTRATIONS, MARKETING AND SALES IN LICENSED TERRITORIES
* PRESTIGE BIOPHARMA - AGREEMENT GRANTS DR. REDDY'S
EXCLUSIVE
RIGHTS TO COMMERCIALIZE PROPOSED BIOSIMILAR IN SOME COUNTRIES IN
LATAM, SOUTHEAST ASIA
Source text for Eikon: urn:newsml:reuters.com:*:nBw5TxF4Ya
Further company coverage: 950210.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prestige Biopharma
See all newsBrief: Prestige Biopharma Wins 2 Billion Won Order
Brief: Prestige Biopharma Receives Final Market Approval From The European Commission For Drug ‘Tuznue,’ For The Treatment Of Breast Cancer And Metastatic Gastric Cancer
Australia's Imagion Biosystems rises on MOU for cancer detection device
Brief: Prestige Biopharma And Intas Pharmaceuticals Announce Partnership To Commercialize Bevacizumab Biosimilar
Brief: Prestige Biopharma Signs Pharmaceutical Contract Manufacturing Agreement With Benevira Inc